Updated:
Axsome Therapeutics
Dr. Herriot Tabuteau, a neurologist by training, founded Axsome Therapeutics in New York in 2012.
Axsome Therapeutics
Dr. Herriot Tabuteau, a neurologist by training, founded Axsome Therapeutics in New York in 2012. The firm structured its R&D around repurposing and reformulating known pharmacologic agents for underserved CNS disorders rather than betting on truly novel molecules. This approach targeted regulatory pathways with lower clinical failure risk and generated a pipeline spanning major depressive disorder, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia. Axsome's late-stage pipeline has produced Auvelity (dextromethorphan-bupropion), an oral NMDA receptor antagonist with a novel mechanism approved for major depressive disorder in 2022, and Symbravo (meloxicam-rizatriptan), an acute migraine treatment cleared by the FDA in early 2025. The firm's commercial strategy is direct — it built its own specialty sales force covering psychiatry and neurology prescribers rather than out-licensing its assets. Active patent challenges from generic manufacturers on Auvelity remain a central operational focus, with settlement discussions and litigation tracked by analysts as the primary near-term risk to its revenue base. Axsome operates from a single headquarters without satellite offices, employing roughly 600 professionals across clinical development, medical affairs, and commercial functions. It has not formed adjacent fund vehicles, philanthropic foundations, or co-investment clubs. In May 2025 the firm raised $500 million in convertible senior notes, earmarked to support the commercial launch of Symbravo and to retire a portion of its existing term loan, signaling a commitment to managing its balance sheet independently of royalty or revenue-sale financing that peers often use. Axsome's structural differentiator is its insistence on retaining full U.S. commercial rights to its neurology assets, a posture that elevates execution risk but preserves downstream economics. Unlike many biotechs that partner after Phase II, Axsome took Auvelity from the lab to the pharmacy shelf with no co-promotion deal, meaning its revenue line maps almost one-to-one onto its own launch competence and patent defense.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Herriot Tabuteau
Chief Executive Officer
Nick Pizzie
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Axsome Therapeutics?
Axsome is a publicly traded commercial-stage biopharmaceutical company, not a fund. Capital allocation decisions — R&D budget, commercial spend, balance-sheet financing — are made by CEO Herriot Tabuteau and CFO Nick Pizzie, with oversight from the board of directors. Major financing events, such as the $500 million convertible note offering in May 2025, are disclosed via SEC filings.
How does Axsome Therapeutics source its pipeline?
Axsome's pipeline historically derives from internal reformulation of existing molecules, not in-licensing or acquisition of external discovery programs. Its lead asset, Auvelity, combined two well-characterized generics into a new patent-protected formulation. The firm's ability to generate new molecular combinations from known compounds is a core sourcing differentiator relative to discovery-stage CNS biotechs.
Does Axsome Therapeutics partner with external GPs or co-investors?
No. Axsome Therapeutics is not a funding vehicle or asset manager. It does not co-invest with external general partners, nor does it operate as a family office or investment firm. It is a publicly traded operating company that raises capital through equity and debt markets, as evidenced by its Nasdaq listing and recent convertible note offering.
Why does Axsome retain full U.S. commercial rights instead of partnering with large pharma?
The firm has publicly articulated a strategy of building a fully integrated CNS company rather than monetizing assets through milestone-and-royalty deals. By retaining rights, Axsome captures the full margin from its specialty sales force's efforts, though it also absorbs the full cost of patent litigation and launch execution. This positions it against large-cap neurology franchises like AbbVie's in migraine and the SSRI/SNRI generic market in depression.
What near-term risks does Axsome face?
Generic manufacturers have filed ANDA challenges against Auvelity, aiming to enter the market before patent expiry. The outcome of this litigation will materially determine Axsome's revenue trajectory. Separately, the commercial launch of Symbravo in a competitive migraine market dominated by oral gepants and injectable CGRP antibodies is a closely watched execution benchmark.
Does Axsome have a philanthropic arm or foundation?
There is no separate philanthropic foundation disclosed in public filings. Axsome's corporate social responsibility, to the extent it exists, is integrated into patient-assistance programs for its commercial drugs rather than structured as a distinct 501(c)(3) vehicle.
What is Axsome's historical burn rate and how does it fund operations?
Axsome has historically funded operations through public equity offerings, convertible debt, and a term loan. The May 2025 convertible note proceeds were partially used to retire higher-cost term loan debt. Revenue from Auvelity contributes to operating cash flow, but the firm has not yet reported sustained profitability.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: